Warberg Asset Management’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Warberg Asset Management’s Portfolio MDNA Stock Details MDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-20,000	Closed	-$5.9K	–	286
2023 Q3	$5.9K	Buy	20,000 +10,000	+100%	+$3.89K	﹤0.01%	195
2023 Q2	$4.82K	Hold	10,000	–	–	﹤0.01%	197
2023 Q1	$6.3K	Sell	10,000 -10,000	-50%	-$6.23K	﹤0.01%	212
2022 Q4	$9.16K	Sell	20,000 -9,500	-32%	-$5.8K	﹤0.01%	207
2022 Q3	$24K	Buy	+29,500	New	+$33.3K	﹤0.01%	196

Other funds holding MDNA

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

NDSI

Newman Dignan & Sheerar Inc Providence, Rhode Island $523M AUM 26.16% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Warberg Asset Management's MDNA Position: Q4 2023 in Review

Warberg Asset Management sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q4 2023, closing a stake of 20,000 shares — an estimated $5.9K sold.

Warberg Asset Management first reported a position in MDNA in Q3 2022 and held it in 5 quarters. The position peaked at $24K in Q3 2022. 3 funds tracked by Wall St. Rank hold MDNA as of Q4 2023.

Warberg Asset Management reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q4 2023 after selling out during the quarter.
Warberg Asset Management sold 20,000 Medicenna Therapeutics Corp. Common Shares shares in Q4 2023, an estimated $5.9K.
Warberg Asset Management first reported a position in Medicenna Therapeutics Corp. Common Shares in Q3 2022 and held it in 5 quarters.
Warberg Asset Management's Medicenna Therapeutics Corp. Common Shares position peaked at $24K in Q3 2022.
3 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q4 2023.

Based on Warberg Asset Management's 13F filing for Q4 2023, filed 7 Feb 2024.